Comparative Pharmacology
Head-to-head clinical analysis: EMGEL versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMGEL versus POLYSPORIN.
EMGEL vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 mL/min).
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic